Enanta Pharmaceuticals Inc (ENTA): [Luly]: “We expect to select a candidate...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119621
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: willyw post# 721

Tuesday, 11/25/2014 1:16:04 PM

Tuesday, November 25, 2014 1:16:04 PM

[Luly]: “We expect to select a candidate from one or more of our proprietary HCV programs and identify a new development candidate in an area beyond HCV.”

[willw]: I'm inferring that one is the NS5A and I hope the other is the nuke, but since Luly twice mentioned the breadth of the HCV program it may mean 2 HCV compounds, not just one.

The above doesn’t refer to EDP-239 (the NS5A inhibitor) because that program already has a lead compound.

As between the nuke program and the cyclophilin-inhibitor program, the question is which will be advanced more rapidly. While it seems that everyone wants it to be the nuke, I’m rooting for the CI because it will have more scarcity value, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”